Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 11/20 | 0.48 |
| ▸ | SLC2A2 | P11168 | 2/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522276 | 0.79 | NR4A2 (0.64) | NR4A2SLC2A1SLC2A2TOP2AMAPT | |
| SCHEMBL6523781 | 0.79 | CYP2C9 (0.62) | NR4A2SLC2A1SLC2A2TOP2ACYP2C9 | |
| SCHEMBL1474667 | 0.78 | NR4A2 (0.79) | NR4A2SLC2A1CYP2C9KDM4ELMNA | |
| SCHEMBL6522800 | 0.76 | SLC2A1 (0.61) | NR4A2SLC2A1SLC2A2TOP2ACYP2C9 | |
| SCHEMBL3498373 | 0.75 | CDH1 (0.50) | SLC2A1SLC2A2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3500174 | 0.73 | SLC2A1 (0.50) | SLC2A1CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL3319550 | 0.70 | FYN (0.60) | — | |
| SCHEMBL16208210 | 0.70 | SLC2A2 (0.47) | SLC2A1SLC2A2TOP2ACYP1A2CYP2C9 | |
| SCHEMBL6525530 | 0.70 | CYP2C9 (0.60) | NR4A2SLC2A1SLC2A2TOP2ACYP2C9 | |
| SCHEMBL6521664 | 0.69 | NR4A2 (0.62) | NR4A2SLC2A1SLC2A2TOP2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262769-B1 | POLYSUBSTITUTED 2-ARYL-6-PHENYL-IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-11-05 | — | — | EP | disclosed |
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065745-A1 | POLYSUBSTITUTED 2-ARYL-6-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC USE THEREOF | JAK2, ABL1, REN | NR4A2 1394/4885SLC2A1 986/4885SLC2A2 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.